Results 61 to 70 of about 3,500 (185)

Bowel Urgency Improvement Correlates With Clinical, Biochemical, and Intestinal Ultrasound Improvements in Inflammatory Bowel Disease: A Cross Sectional Multicenter Study

United European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Bowel urgency (BU) is reported by over 80% of patients with ulcerative colitis (UC) and 60% of those with Crohn's disease (CD). However, the impact of advanced therapies on BU has not been consistently evaluated. Objectives To assess the effect of advanced therapies on BU improvement in patients with UC and CD.
Ferdinando D'Amico, Olga Maria Nardone, Alessandro Bruno, Mariangela Allocca, Alessandra Zilli, Federica Furfaro, Tommaso Lorenzo Parigi, Virginia Solitano, Federica Ungaro, Ilaria Faggiani, Alessia La Mantia, Giulio Calabrese, Gionata Fiorino, Vipul Jairath, Laurent Peyrin‐Biroulet, Luca Massimino, Fabiana Castiglione, Silvio Danese   +17 more
wiley   +1 more source

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjogren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study [PDF]

, 2022
OBJECTIVE: The aim of this study was to characterize the safety and efficacy of filgotinib, lanraplenib and tirabrutinib in patients with active SS. METHODS: This multicentre, double-blind study randomized patients with active primary or secondary SS ...
Bombardieri, M, Downie, B, Gottenberg, JE, Gurtovaya, O, Jiang, W, Kivitz, A, Mathur, A, Matzkies, F, Mozaffarian, A, Mozaffarian, N, Pechonkina, A, Price, E   +11 more
core   +1 more source

Successful treatment of rheumatoid arthritis‐associated interstitial lung disease with filgotinib: A case report on janus kinase 1 inhibition

Respirology Case Reports
Filgotinib, a janus kinase 1 (JAK1) inhibitor, is used in the treatment of rheumatoid arthritis (RA). RA‐associated interstitial lung disease (RA‐ILD) is a severe RA complication with no established effective treatment.
Atsuhiko Sunaga, Takuya Inoue
doaj   +1 more source

Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post hoc Analysis of the Phase 2b/3 SELECTION Study [PDF]

BACKGROUND AND AIMS: SELECTION is the first study to assess the impact of concomitant thiopurine and other immunomodulator [IM] use on the efficacy and safety of a Janus kinase inhibitor, filgotinib, in patients with ulcerative colitis.
Danese, Silvio, Faes, Margaux, Fujitani, Yasushi, Hibi, Toshifumi, Lindsay, James O, Oortwijn, Alessandra, Peyrin-Biroulet, Laurent, Rogler, Gerhard, Watanabe, Kenji   +8 more
core   +1 more source

Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE [PDF]

, 2023
BACKGROUND: Filgotinib 200 mg (FIL200) is an approved treatment for adults with moderately to severely active ulcerative colitis (UC). AIM: To report integrated safety data from the phase 2b/3 SELECTION study (NCT02914522) and its ongoing long-term ...
Danese, Silvio, de Haas, Angela, Faes, Margaux, Hsieh, Jeremy, Loftus, Edward V, Maaser, Christian, Moerch, Ulrik, Oortwijn, Alessandra, Rogler, Gerhard, Rudolph, Christine, Schreiber, Stefan, Van Hoek, Paul, Vermeire, Séverine, Watanabe, Mamoru, Zhou, Yan   +14 more
core   +1 more source

ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice [PDF]

, 2023
Background: Filgotinib (FIL) is a selective JAK1 inhibitor with an affinity 30-fold higher than JAK2, approved to treat moderate to severe active rheumatoid arthritis (RA), in adults with inadequate response or intolerance to one or more disease ...
Bardelli M., Bartoli F., Benucci M., Cantini F., Cazzato M., Damiani A., Di Cato L., Frediani B., Guiducci S., Laurino E., Li Gobbi F., Mosca M., Niccoli L., Panaccione A.   +13 more
core   +1 more source

Filgotinib for treating moderate to severe rheumatoid arthritis [PDF]

Prescriber, 2021
Filgotinib (Jyseleca) is a new oral janus kinase (JAK) inhibitor that has recently been approved by NICE for moderate or severe rheumatoid arthritis after failure of other disease‐modifying antirheumatic drugs (DMARDs). This article discusses its efficacy, side‐effects and place in therapy.
openaire   +1 more source

Inflammatory bowel disease and metabolic reprogramming: From pathological mechanisms to targeted interventions

Interdisciplinary Medicine, Volume 4, Issue 1, January 2026.
This review explores the role of metabolic reprogramming in inflammatory bowel disease (IBD) by focusing on immune and epithelial cell metabolism, microbial metabolites, and their impact on inflammation. It discusses emerging metabolic therapies and emphasizes the importance of personalized microbiota‐targeted approaches to improve clinical outcomes in
Zemin Tian, Yinde Huang, Ying Wang, Chenyu Zhao, Zhaokai Zhou, Hua Yang, Yuan Qiu   +6 more
wiley   +1 more source

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

RMD Open
Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs.
Hendrik Schulze-Koops, Tsutomu Takeuchi, Daniel Aletaha, Maya H Buch, Yoshiya Tanaka, Ricardo Blanco, Paul Emery, Jacques-Eric Gottenberg, Bernard G Combe, Roberto Caporali, Patrick Verschueren, Vijay Rajendran, Anna Zubrzycka-Sienkiewicz, Edmund V Ekoka Omoruyi, Francesco De Leonardis   +14 more
doaj   +1 more source

Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team [PDF]

Intestinal Research
Janus kinase (JAK) inhibitors are an important treatment option for ulcerative colitis, providing rapid onset of action, oral administration, and efficacy even after biologic failure. The 3 approved agents—tofacitinib, filgotinib, and upadacitinib—differ
Seung Min Hong, Dong Hyun Kim, June Hwa Bae, Seung Yong Shin, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Seong-Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Miyoung Choi, Myung Ha Kim, Won Moon, Sung-Ae Jung,   +20 more
doaj   +1 more source